Fresenius Medical Care presented new research highlighting ongoing innovation at the European Renal Association Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlighted advancements including new hemodiafiltration research that reaffirm its leadership in evidence based and personalized dialysis care, real-world evidence to strengthen patient centered outcomes across dialysis modalities, and the application of artificial intelligence to improve patient outcomes. FME's Global Medical Office and Renal Research Institute teams presented multiple abstracts across a range of critical topics in nephrology, demonstrating how data, artificial intelligence, and patient-centered outcomes are shaping the future of kidney care.
Key presentations included: Impact of Matching and Weighting Strategy on Patient Retention and 3-Year Mortality in Real-World Hemodialysis and Hemodiafiltration: In a real-world analysis, hemodiafiltration was associated with lower three-year mortality risk than hemodialysis, with consistent results across different comparison methods. The Association Between Patient-Reported Dialysis Recovery Time and Missed Treatments: Hemodialysis patients who reported longer recovery times after treatment also had a higher number of missed treatments. Clinics' Utilization of an AI-Based Model Predicting Peritoneal Dialysis Dropouts Is Associated with Lower Hospitalization Rates: Clinics with higher use of an AI-based dashboard for identifying peritoneal dialysis patients at risk of dropping out saw lower all-cause hospitalization rates.
A High-Precision Large-Language Model Approach for Abstract Screening in Systematic Reviews: GPT-5 may help researchers sort through large numbers of research studies by identifying ones that are most relevant. As part of its broader innovation portfolio highlighted at the Congress, FME previews kinexus, a unified digital platform for home dialysis. Designed as a single, integrated ecosystem, kinexus brings together remote therapy management and operational workflows to help simplify care processes for healthcare teams and support high-quality, personalized care for patients dialyzing at home.
Huma Therapeutics Limited is the digital health platform partner and legal manufacturer of kinexus. Fresenius Medical Care Deutschland GmbH acts as the authorized distributor.
